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analysis with more advanced RT technique is needed to 
assess the future role of RT in orbital tumors. 
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Purpose or Objective: Breast cancer patients receiving post-
operative radiotherapy (RT) experience adverse effects and 
general fatigue is one of them. Although it is often not severe 
enough to interrupt the course of RT, it negatively affects 
quality of life. Some Japanese herbal medicines such as TJ-41 
(Hochu-ekki-to) are effective for fatigue and are often used 
in daily practice. The purpose of this study is to assess 
radiation-induced fatigue (RIF) in detail and investigate the 
effect of Japanese herbal medicine. 
 
Material and Methods: Breast cancer patients who received 
post-operative RT and agreed to answer a patient self-
reporting questionnaire (FACIT-F; Functional Assessment of 
Chronic Illness Therapy) were eligible for this study. We 
excluded patients who were receiving chemotherapy 
concurrently. RIF was defined as fatigue which occurred 
during the period of radiotherapy and there were no causes 
for the fatigue other than the radiotherapy. The FACIT-F 
questionnaire was answered before RT, at one week after the 
beginning of RT, at the end of RT and one month after the 
end of RT. We prescribed TJ-41 to the RIF patients during the 
radiotherapy. We defined as responders the patients who 
experienced improvements in RIF and hoped for further 
prescription. 
 
Results: Fifty-two patients were enrolled for this study. RIF 
was observed in 24 (46 %) patients. On univariate analysis, 
the statistically significant predictor of RIF was the score of 
FACIT-F before RT. TJ-41 was administered to 9 patients and 
8 of them (89 %) were responders. 
 
Conclusion: RIF was common in breast cancer patients 
receiving post-operative RT and TJ-41 was effective for the 
RIF patients and improved their quality of life. However, 
these results may lack objectivity and the study was 
conducted with no placebo group. Improvement in objectivity 
of the assessment and a comparative study will be needed. 
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Purpose or Objective: Hyperthermia is a powerful 
radiosensitizer for treatment of superficial tumors. Several 
trials showed an advantage of combining radiotherapy with 
hyperthermia in terms of both local tumor control and overall 
survival. The purpose of this study is to evaluate both 
efficacy and toxicity of radiotherapy-hyperthermia (RT-HT) in 
the treatment of superficial recurrent and metastatic tumors 
in patients previously or not previously irradiated. 
 
Material and Methods: In our Institution twenty-three 
patients (mean age 71,4 years; range: 51-88) with 
histologically confirmed superficial recurrent/metastatic 
tumors were enrolled: 11 breast carcinoma, 6 head&neck 
cancer, 2 malignant melanoma, 2 sarcomas, 1 uterine 
adenocarcinoma and 1 hepatocarcinoma. Patients underwent 
radiotherapy treatment using 3D-conformal radiotherapy 
(8/23) or Helical Tomotherapy (15/23). External beam 
radiotherapy was delivered in 6-27 fractions of 1.8-5 Gy for a 
total dose of 20-57.5 Gy (mean external dose: 41 Gy). 
Prescribed dose was established taken into account, of the 
previous radiation doses, in previously irradiated patients, 
Karnofsky performance status and patient compliance. 
Hyperthermia treatment was performed with an 
electromagnetic superficial applicator operating at the 
frequency of 434 MHz. HT session was delivered once/twice 
weekly during the period of external radiotherapy, 1-2 hours 
after radiotherapy, to a mean total of 5 treatments [range: 
1-9 sessions]. Termocouples were used to evaluate 
temperature distribution map. Average, maximum and 
minimum temperature parameters were recorded during 
hyperthermia treatment. The treatment goal was to reach 
40- 42°C in > 90% (T90) of measured points for a duration of 
60 minutes. Acute and late toxicity was evaluated according 
to the CTCAE criteria. Local control was assessed after the 
end of the treatment on the basis of the RECIST Criteria.  
 
Results: During hyperthermia treatment the median 
temperature reached was 40.5 °C [range: 39 – 42.9°C]. 
During the radiotherapy in association with hyperthermia 2 
pts (10%) had G3 toxicity and one of these interrupted the 
treatment. One pt had acute cutaneous toxicity ≥ G3 at 1 
month. No pts had toxicity ≥ G2 at 3 and 6 months. No 
toxicity was observed at 12 months. The mean follow-up was 
10 months (range 3-22 months). Four pts (17%) had a 
complete response (CR), 11 pts ( 48%) had a partial response 
(PR),7 pts (30%) had a stable disease, (SD) and only 1 pt (4%) 
had progression disease (PD) and subsequently died. The 
Local control rate was 95%. Univariate analysis showed that 
Tmean,Tmax, Tmin,T90 parameters were not associated with 
local control rate.  
 
Conclusion: Radio-hyperthermia can result in an effective 
approach, particularly in previously irradiated patients or in 
radio-resistant tumors. Our results show that Radio-
Hyperthermia is an useful combined treatment with a good 
local control rate and a very high patient compliance.  
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Purpose or Objective: The purpose of this study is to 
evaluate the decrease in pain of patients treated with low-
dose radiation therapy in osteoarthritis. 
 
Material and Methods: From April 2015 to September 2015, 
11 patients (10 female and 1 men) were treated with low 
dose radiotherapy for pain control. All patients were 
refractory to conventional therapy prior to irradiation.  
13 joints (6 bursitis and 7 arthrosis): 4 trochanteritis, 5 
knees, 1 left thumb rhizarthrosis, 2 metacarpophalangeal 
joint and 1 right epicondylitis were treated.  
The median age was 69 years (range 46-89) with a median 
follow-up period of 3 months (range 0-6). Painful status was 
measured by visual analogue scale (VAS), with a median pre-
treatment value of VAS= 7(range 4-9).  
The radiotherapy dose of 6 Gy was delivered in 6 alternate 
days fractions of 1 Gy per fraction. In those patient with no 
pain relive post-treatment with VAS of or above 6 a second 
course of radiotherapy was proposed.  
The second RT series started 8 weeks after the first RT 
series.  
 
Results: The analysis was performed before the treatment 
and at the last follow-up. With a median VAS = 5 (range 0-8) 
7 patients achieved pain relief, 3 patients underwent a 
second course of radiotherapy with identical dose, and 1 
patient showed no change in pain. Daily requirements of 
analgesic were removed of reduced in 5 patients, subjective 
pain perception of response to irradiation evaluated at time 
of last visit regarding pre-treatment status was considered as 
“better” by 73% of patient. No patients presented acute or 
late complications attribute to radiation therapy. 
